

=> fil hcaplu

FILE 'HCAPLUS' ENTERED AT 14:40:52 ON 12 JUN 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Jun 2003 VOL 138 ISS 24

FILE LAST UPDATED: 11 Jun 2003 (20030611/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d stat que

L1 2 SEA FILE=REGISTRY KMVIYWKAG/SQSP
L2 3 SEA FILE=HCAPLUS L1

=> d ibib abs hitrn 12 1-3

L2 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2003:319448 HCAPLUS

DOCUMENT NUMBER: 138:331672

TITLE: Compounds and methods for modulating cell adhesion-mediated drug resistance

INVENTOR(S): Dalton, William S.; Damiano, Jason S.; Cress, Anne E.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 47 pp., Cont. Ser. No. US 2001-795484, filed on 1 Mar 2001

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003078210	A1	20030424	US 2001-24017	20011221
PRIORITY APPLN. INFO.:		US 2001-795484 A1 20010301		
AB Peptides and methods of their use for inhibiting drug and radiation-therapy resistance in cancerous cells in which efficacy of chemotherapy and/or radiotherapy of a patient is enhanced by administration of an effective amt. of a peptide that inhibits cell adhesion-mediated drug resistance (CAM-DR). Preferably, the peptide comprises D-amino acids having the sequence: kmviywkag (RZ-3) or is a variant or modified version thereof. The peptide is preferably administered to the patient prior to chemotherapy and/or radiation therapy. Inhibition of CAM-DR by RZ-3 in multiple myeloma cells is				

Searched by M. Smith

disclosed.

IT 514181-06-7

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
(Uses).

(peptides modulating cell adhesion-mediated drug resistance)

L2 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:661456 HCAPLUS

DOCUMENT NUMBER: 135:221277

TITLE: Peptides and methods for modulating cell
adhesion-mediated drug resistance

INVENTOR(S): Dalton, William S.; Damiano, Jason S.; Cress, Anne E.

PATENT ASSIGNEE(S): University of South Florida, USA

SOURCE: PCT Int. Appl., 78 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001064714	A2	20010907	WO 2001-US6397	20010301
WO 2001064714	A3	20020328		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-186198P P 20000301

AB The invention discloses peptides and methods of their use for inhibiting
drug- and radiation-therapy resistance in cancerous cells, in which
efficacy of chemotherapy and/or radiotherapy of a patient is enhanced by
administration of an effective amt. of a peptide that inhibits cell
adhesion-mediated drug resistance (CAM-DR). Preferably, the peptide
comprises D-amino acids having the sequence: kmviywkg (RZ-3), or is a
variant or modified version thereof. The peptide is preferably
administered to the patient prior to chemotherapy and/or radiation
therapy. Inhibition of CAM-DR by RZ-3 in multiple myeloma cells is
disclosed.

IT 351327-12-3 351327-12-3D, variants

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(peptides and methods for modulating cell adhesion-mediated drug
resistance)

L2 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:310071 HCAPLUS

DOCUMENT NUMBER: 135:116754

TITLE: Synthetic peptides inhibit adhesion of human tumor
cells to extracellular matrix proteins

AUTHOR(S): DeRoock, Ian B.; Pennington, Michael E.; Sroka, Thomas
C.; Lam, Kit S.; Bowden, G. Tim; Bair, Elisabeth L.;

Cress, Anne E.
CORPORATE SOURCE: Department of Radiation Oncology, The Arizona Cancer
Center, University of Arizona, Tucson, AZ, 85724-5024,
USA
SOURCE: Cancer Research (2001), 61(8), 3308-3313
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Human tumor cell progression and metastasis are partially dependent on the ability of a tumor cell to adhere to the proteins of the extracellular matrix (ECM) and survive at the distant location. Six novel D-amino acid-contg. peptides were analyzed for their ability to adhere to human prostate tumor cells, support tumor cell adhesion, and inhibit tumor cell adhesion to ECM proteins or human dermal fibroblasts. Of these, two peptides called RZ-3 (kmviywkag) and HYD-1 (kikmviswkg) bound to tumor cell surfaces and compared favorably with the previously reported AG-73 (RKRLQVQLSIRT) L-amino acid peptide, as detd. by fluorescence-activated cell sorting anal. A scrambled peptide deriv. of HYD-1, called HYDS-1 (wiksmkivkg), was not active. The RZ-3, HYD-1, and AG-73 peptides supported maximal cancer cell adhesion at 5 .mu.g, 10 .mu.g, and 50 .mu.g/well, resp. The ECM proteins fibronectin, laminin 1, and collagen IV supported maximal cell adhesion at 1 .mu.g, >10 .mu.g, and 50 .mu.g/well, resp. Prostate tumor cell adhesion to immobilized RZ-3 and HYD-1 peptides was inhibited by .alpha.2-6- and .beta.1-integrin-blocking antibodies. Conversely, tumor cell adhesion to a .beta.1-integrin-specific antibody was blocked by both RZ-3 and HYD-1. Epithelial cell adhesion to dermal fibroblasts was inhibited by HYD-1 and unaffected by the scrambled peptide, HYDS-1. Cell adhesion to immobilized peptides was unaffected by EDTA. The sol. RZ-3 and HYD-1 peptides inhibited tumor cell adhesion to each of the immobilized four ECM proteins (1.0 .mu.g/well) in a time- and concn.-dependent manner. The IC50 of the RZ-3 peptide for blocking adhesion to fibronectin, laminin 1, laminin 5, and collagen IV was 2.4 .mu.g, 1.8 .mu.g, 4.6 .mu.g, and 2.8 .mu.g/well, resp. The IC50 of the HYD-1 peptide for blocking adhesion to fibronectin, laminin 1, laminin 5, and collagen IV was 6.9 .mu.g, 5.7 .mu.g, >10 .mu.g, and 6.2 .mu.g/well, resp. Taken together, these results indicate that RZ-3 and HYD-1 are biol. active D-amino acid-contg. peptides that can themselves support tumor cell adhesion and can inhibit tumor cell adhesion to immobilized ECM proteins or dermal fibroblasts.

IT 351327-12-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(peptides inhibit adhesion of human tumor cells to extracellular matrix proteins)

REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> fil reg

FILE 'REGISTRY' ENTERED AT 14:41:32 ON 12 JUN 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 JUN 2003 HIGHEST RN 529474-19-9

Searched by M. Smith

DICTIONARY FILE UPDATES: 11 JUN 2003 HIGHEST RN 529474-19-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s 12

L3 2 L1

=> d rn cn lc nte sql kwic can tot 13

L3 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2003 ACS

RN 514181-06-7 REGISTRY

CN Glycine, L-lysyl-L-methionyl-L-valyl-L-isoleucyl-L-tyrosyl-L-tryptophyl-L-lysyl-L-alanyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN RZ-3

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

SQL 9

SEQ 1 KMVIYWKAG

=====

HITS AT: 1-9

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 138:331672

L3 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2003 ACS

RN 351327-12-3 REGISTRY

CN Glycine, D-lysyl-D-methionyl-D-valyl-D-isoleucyl-D-tyrosyl-D-tryptophyl-D-lysyl-D-alanyl- (9CI) (CA INDEX NAME)

LC STN Files: CA, CAPLUS, TOXCENTER

SQL 9

SEQ 1 KMVIYWKAG

=====

HITS AT: 1-9

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 135:221277

REFERENCE 2: 135:116754